Many therapeutic strategies are continuously being investigated to find the means to effectively treat cancer. Immunotherapeutic approaches are emerging as very valuable options for patients with different types of cancer. Many of the approaches involve targeting the adaptive immune system. The adaptive immune system involves targeting specifically identified cells by cytotoxic T cells and represents a specialized attack on invading and pathogenic (disease-causing) cells and molecules.
Regulatory T cells (Tregs) are immune cells that function to regulate the immune system in order to prevent autoimmune disease. They do this by sustaining immune tolerance to the body’s own cells and antigens. Tregs are known to have interleukin 2 receptors (IL-2R), and their functions depend on interleukin 2 (IL-2), a cytokine that is released by T helper cells and act on cytotoxic T cells.